Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
In mammalians, toll-like receptors (TLR) signal-transduction pathways induce the expression of a variety of immune-response genes, including inflammatory cytokines. It is therefore plausible to assume that TLRs are mediators in glial cells triggering the release of cytokines that ultimately kill DA neurons in the substantia nigra in Parkinson disease (PD). Accordingly, recent data indicate that TLR4 is up-regulated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment in a mouse model of PD. Here, we wished to evaluate the role of TLR4 in the acute mouse MPTP model of PD: TLR4-deficient mice and wild-type littermates control mice were used for the acute administration way of MPTP or a corresponding volume of saline. We demonstrate that TLR4-deficient mice are less vulnerable to MPTP intoxication than wild-type mice and display a decreased number of Iba1+ and MHC II+ activated microglial cells after MPTP application, suggesting that the TLR4 pathway is involved in experimental PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TLR4 gene-deficient mice partially resist MPTP toxicity by suppressing the activation of microglia in the substantia nigra.156”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [156]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene
Poltorak, A., He, X., Smirnova, I., Liu, M.-Y., Huffel, C. V., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., et al. (1998) · Science · doi:10.1126/science.282.5396.2085 · Cited by 7,631
mouse brain in stereotaxic coordinates
Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Self-citationMelanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301
Brochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.-M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36470 · Cited by 1,172
Self-citationTargeting Toll-like receptors: emerging therapeutics?
Hennessy, E. J., Parker, A. E., & O'Neill, L. A. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3203 · Cited by 886
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869
LAFLAMME, N., & RIVEST, S. (2001) · The FASEB Journal · doi:10.1096/fj.00-0339com · Cited by 501
Moresco, E. M. Y., LaVine, D., & Beutler, B. (2011) · Current Biology · doi:10.1016/j.cub.2011.05.039 · Cited by 500
Research works printed but not linked: 1
- Fahn S., Parkinsonism P. S., & Rowland L. P. ed. Meritt's neurology 10th ed. New York: Lippincott, 2000, 679–693 (2000).
Cited by
Items 101–162 of 162
Crosstalk Between Insulin and Toll-like Receptor Signaling Pathways in the Central Nervous system
Hemmati, F., Ghasemi, R., Ibrahim, N. M., Dargahi, L., Mohamed, Z., Raymond, A. A., & Ahmadiani, A. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8631-3 · Cited by 24
Neurobehavioral Anomalies in the Pitx3/ak Murine Model of Parkinson’s Disease and MPTP
Filali, M., & Lalonde, R. (2015) · Behavior Genetics · doi:10.1007/s10519-015-9753-3 · Cited by 23
“To determine further the possible role of dopamine in this mutant, mice on the same B6 background strain were injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin after transformation into the MPP ? ion (Tipton and Singer 1993) in a process mediated by Toll-like receptor 4 (Noelker et al. 20…”
Low‐variance RNAs identify Parkinson's disease molecular signature in blood
Chikina, M. D., Gerald, C., Li, X., Ge, Y., Pinças, H., Nair, V. D., Wong, A. K., Krishnan, A., Troyanskaya, O. G., Raymond, D., et al. (2015) · Movement Disorders · doi:10.1002/mds.26205 · Cited by 21
“5 (1-65) % definitely on L-dopa N/A N/A 70.”
Toll Like Receptor 4 Affects the Cerebral Biochemical Changes Induced by MPTP Treatment
Conte, C., Roscini, L., Sardella, R., Mariucci, G., Scorzoni, S., Beccari, T., & Corte, L. (2017) · Neurochemical Research · doi:10.1007/s11064-016-2095-6 · Cited by 24
Zhao, R., Mu, B., Wang, D., XinHuang, Ma, Q., & Lu, M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04584-9 · Cited by 29
“Interestingly, Noelker et al. found that genetic deletion of TLR4 signaling protected mice from neurodegenerative lesions, suggesting an important role of TLR4 in PD development [136].”
Dual Roles of Microglia in the Basal Ganglia in Parkinson’s Disease
Choudhury, M. E., Kigami, Y., & Tanaka, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083907 · Cited by 19
Kumari, A., Srivastava, A., Jagdale, P. R., Ayanur, A., & Khanna, V. K. (2023) · NeuroToxicology · doi:10.1016/j.neuro.2023.04.003 · Cited by 21
Hopp, M.-T., Holze, J., Lauber, F., Holtkamp, L., Rathod, D., Miteva, M. A., Prestes, E. B., Geyer, M., Manoury, B., Merle, N. S., et al. (2023) · Immunology · doi:10.1111/imm.13708 · Cited by 19
“As a part of the innate immune system, Toll-like receptor 4 (TLR4) plays a crucial role in the progression of several infections (e.g., Gram-negative bacteria [1] and SARS-CoV-2 [2]) and non-infectious diseases (e.g., kidney ischemia/reperfusion injury [3] and neurodegenerative diseases [4 – 6]).”
BackgroundTiwari, R. K., Moin, A., Rizvi, S. M. D., Shahid, S. M. A., & Bajpai, P. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00696-6 · Cited by 20
Prothrombin Kringle-2: a potential inflammatory pathogen in the parkinsonian dopaminergic system
Leem, E., Jeong, K. H., Won, S.-Y., Shin, W.-H., & Kim, S. R. (2016) · Experimental Neurobiology · doi:10.5607/en.2016.25.4.147 · Cited by 16
Somensi, N., Lopes, S. C., Gasparotto, J., Gonçalves, R. M., Ribeiro, C. T., Peixoto, D. O., Brum, P. O., Pinho, C. M., Agnes, J. P., Santos¹, L. F. D. S., et al. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105215 · Cited by 22
TLR4 in Tph2 neurons modulates anxiety-related behaviors in a sex-dependent manner
Li, Y., Zhu, S., Xie, K., Feng, X., Chen, L., Wu, X., Sun, Z., Shu, G., Wang, S., Zhu, C., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109175 · Cited by 16
Neal, M. P., Beier, E. E., Hossain, M. M., Boyle, A. M., Zheng, J., Kim, C., Mhatre‐Winters, I., Wu, L., & Richardson, J. R. (2023) · Antioxidants · doi:10.3390/antiox12030582 · Cited by 17
“jected once every two hours for four total injections, and the mice were sacrificed either 2 or 7 days later [64,65].”
MethodTang, T., Guo, Y., Xu, X., Zhao, L., Shen, X., Sun, L., & Xie, P. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27212 · Cited by 15
Zhang, Q., Zhao, Y., Xi, J., Yu, W., & Xiao, B. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5889 · Cited by 16
“Furthermore, corresponding inflammatory conditions have been described in toxin-based parkinsonism models, with high levels of microglia in the SN (36-40).”
T-cell based immunotherapies for Parkinson’s disease
Pacheco, R. (2021) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2021.00007 · Cited by 11
“In this regard, it has been described that initial microglial activation is triggered by pathogenic forms of αSyn, which stimulate toll-like receptors (TLRs) on these cells [4, 5].”
BackgroundTumpa, J. J., Hayder, Q. U. A., Maisa, N. S., & Islam, M. N. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1682006 · Cited by 18
“Studies have shown that the genetic absence of TLR4 signaling in mouse models protects the animal from neurodegeneration, highlighting its role in PD (Noelker et al., 2013).”
e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease
Cataldi, S., Codini, M., Hunot, S., Légeron, F.-P., Ferri, I., Siccu, P., Sidoni, A., Ambesi‐Impiombato, F. S., Beccari, T., Curcio, F., et al. (2016) · Mediators of Inflammation · doi:10.1155/2016/3937057 · Cited by 13
“Administration of MPTP has had dangerous effects on dopaminergic neurons of the nigrostriatal pathway in animals to produce experimental model of parkinsonism [1–4] with neuroinflammatory mechanisms [23].”
BackgroundSelf-citationToll-like receptor 4-mediated signaling participates in apoptosis of hippocampal neurons.
He, Y., Zhou, A., & Jiang, W. (2013) · PubMed Central · doi:10.3969/j.issn.1673-5374.2013.29.006 · Cited by 17
“TLR4 has also been shown to be connected with neurodegenerative diseases [30-33] .”
BackgroundHernández-Plata, I., Rodríguez, V. M., Tovar‐Sánchez, E., Carrizalez, L., Villalobos, P., Mendoza-Trejo, M. S., & Mussali-Galante, P. (2020) · Environmental Science and Pollution Research · doi:10.1007/s11356-020-09451-3 · Cited by 13
“…suggest that possible modifications in behavioral performance could cause alterations in breeding and/or survival and long-term effects that may have negative consequences at the population level (Basu et al. 2005a, b; Hellou 2011; Nam et al. 2012; Ostertag et al. 2013, 2014; Krey et al. 2015).”
BackgroundGao, J., Zhang, W., Chai, X., Tan, X., & Yang, Z. R. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.11.011 · Cited by 11
An Infection Hypothesis of Parkinson’s Disease
Karpenko, M. N., Muruzheva, Z. M., Pestereva, N. S., & Ekimova, I. V. (2019) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-019-00769-1 · Cited by 9
Yang, J., Lin, W., Ma, Y., Song, H., Mu, C., Wu, Q., Chen, H., Zhang, J., & Liu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1370831 · Cited by 12
Sirtuins in Parkinson's disease: Molecular mechanisms and pathophysiological roles
Li, X., Luo, X., Cao, X., Thomas, E. R., Wang, W., Zhou, X., Zhou, S., Wu, A., Gao, R., Liu, K., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102902 · Cited by 9
Halder, A., Yadav, K., Aggarwal, A., Singhal, N. K., & Sandhir, R. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109714 · Cited by 9
Xia, Y., Chen, C., Chen, J., Hu, C., Yang, W., Wang, L., Liu, L., Gao, L.-P., Wu, Y.-Z., Chen, D.-D., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02989-y · Cited by 7
Martínez‐Gopar, P. E., Pérez‐Rodríguez, M. J., Angeles-López, Q. D., Tristán-López, L. A., González‐Espinosa, C., & Pérez‐Severiano, F. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03234-w · Cited by 8
Li, Z., Lv, H., Cui, X., Wei, D., Cheng, X., Liu, J., & Tripathi, A. S. (2023) · Folia Neuropathologica · doi:10.5114/fn.2023.132424 · Cited by 8
“Moreover, TLR4 is reported to be upregulated in MPTP treated rats [15] as data of the present study also support.”
Cannflavin A inhibits TLR4-induced chemokine and cytokine expression in human macrophages
Fitzpatrick, J.-M., O’Riordan, D., & Downer, E. J. (2024) · Natural Product Research · doi:10.1080/14786419.2024.2358382 · Cited by 7
“Innate immune responses via TLR4 in macrophages mediates inflammation at a cellular level (Zuniga et al. 2017) and importantly, TLR4 signalling can contribute to disease progression, with signalling via this receptor linked to ischemia-reperfusion injury (Oyama et al. 2004) and the pathogenesis of MS (Marta et al. 200…”
Nazif, N. N., Khosravi, M., Ahmadi, R., Bananej, M., & Majd, A. (2020) · PubMed Central · doi:10.22038/ijbms.2020.37707.8960 · Cited by 11
“The widely-used 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) mouse model of PD is characterized by substantial gliosis linked to activated astroglia and microglia (6).”
BackgroundFernagut, P. (2016) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-802206-1.00040-4 · Cited by 8
Overview of Mechanisms Underlying Neuroimmune Diseases
Sonar, S. A., & Lal, G. (2019) · Contemporary clinical neuroscience · doi:10.1007/978-3-030-19515-1_1 · Cited by 6
Xia, Y., Ye, S., Shi, J., & Huang, H. (2018) · Brazilian Archives of Biology and Technology · doi:10.1590/1678-4324-2018160721 · Cited by 5
Nutraceuticals a Food for Thought in the Treatment of Parkinson’s Disease
Bansal, K., Singh, S., Singh, V., & Bajpai, M. (2023) · Current Nutrition & Food Science · doi:10.2174/1573401319666230515104325 · Cited by 5
Panaro, M. A., Carofiglio, V. E., Calvello, R., Aloisi, A., Rinaldi, R., Nicolardi, G., Lofrumento, D. D., Nuccio, F. D., Pesa, V. L., Fontani, V., et al. (2015) · Mediterranean Microwave Symposium · doi:10.1109/mms.2015.7375415 · Cited by 4
“in the SN, suggesting that dopaminergic cell death in this model is, at least to some extent, TLR4-dependent as TLR4deficient mice display an increased number of surviving TH+ neurons compared to wild type mice [32].”
ResultLiu, B., Lv, C., Zhang, J., Liu, Y., Sun, J., Cheng, X., Mao, W., Ma, Y., & Li, S. (2017) · Neurological Research · doi:10.1080/01616412.2017.1297911 · Cited by 4
Parkinson’s disease: exploring the systemic immune mechanisms through molecular investigations
Mohan, M., Mannan, A., & Singh, T. G. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01816-9 · Cited by 3
“In an acute MPTP-induced mouse model, TLR4-deficient mice showed reduced immune response and neurodegeneration compared to wild-type, confirming TLR4’s role in PD pathogenesis (Noelker et al. 2013).”
TLR4 in Neurodegenerative Diseases: Alzheimer’s and Parkinson’s Diseases
Balducci, C., & Forloni, G. (2020) · Progress in inflammation research · doi:10.1007/978-3-030-56319-6_7 · Cited by 4
Kaur, G., Behl, T., Sehgal, A., Singh, S., Sharma, N., Kumar, A., Arora, S., & BUNGAU, S. G. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01811-z · Cited by 3
RetractedBhardwaj, K., Singh, A. A., & Kumar, H. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00293 · Cited by 4
Wei, X., Cui, Y., Lin, Y., Xiang, J., Zhu, K., Xiang, H., & Wang, M. (2025) · Insect Science · doi:10.1111/1744-7917.70077 · Cited by 2
“That is, these genes not only combat microbial infections by producing antimicrobial peptides but also participate in neurological development, neuronal apoptosis and neurological disorders (Larsen et al. , 2007; Hanafy, 2013; Noelker et al. , 2013; Hu et al. , 2021).”
Pan, H.-L., Ge, J.-Y., Zhang, Z.-A., Xu, J., Wu, J., Ju, Y., Zhang, X.-Y., Jiang, Z.-J., Chen, Y., Xu, Y., et al. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109016 · Cited by 5
Alpha-synuclein and neuroinflammation in Parkinson's disease
Varanita, T., & Bubacco, L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815950-7.00027-8 · Cited by 2
Gut–Brain Axis: Role of Gut Microbiota in Neurodegenerative Disease
Narang, A., & Sandhir, R. (2022) · Springer eBooks · doi:10.1007/978-981-16-6760-2_1 · Cited by 1
Zhu, S., Zhou, Y., Ye, Z., Sun, M., Shu, G., Wang, S., Jiang, Q., & Wang, L. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106469 · Cited by 2
Cellular and Molecular Mechanisms Contributing to Parkinson’s Disease
Madhuranthagan, M., Benito Johnson., D., Essly Selva Jasmine., P., Suresh., R., & Senthil Kumar., C. (2026) · Research Journal of Pharmacology and Pharmacodynamics · doi:10.52711/2321-5836.2026.00005 · Cited by 1
Özata, G., Wise, R. M., Cardona‐Alberich, A., Mayeen, N. F., Müller, S. A., Lichtenthaler, S. F., Zecca, L., & Burbulla, L. F. (2026) · Scientific Reports · doi:10.1038/s41598-026-55648-w · Cited by 1
Herenbrink, C. K., Støier, J. F., Reith, W. D., Dagra, A., Gregorek, M. A. C., Li, Y., Tian, L., Gether, U., & Herborg, F. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.16.460471 · Cited by 1
Role of microglia in myelin turnover
Safaiyan, S. (2016) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5727
Mikroglial Toll-benzeri Reseptörlerin Alzheimer ve Parkinson Hastalıklarındaki Rolü
Samur, D. N., & Özbey, G. (2021) · Akdeniz Medical Journal · doi:10.53394/akd.981907 · Cited by 1
Rungruang, P., Sansri, V., & Sroyraya, M. (2024) · Neuroscience Research Notes · doi:10.31117/neuroscirn.v7i1.271
“…MPTP provided evidence that several TLRs (TLR3, TLR4, TLR7, and TLR9), along with the MyD88 gene (key adaptor in the TLR signalling pathway), were shown to be involved in mediating cell death in the mouse model of Parkinson's disease induced by MPTP (Ros-Bernal et al., 2011; Noelker et al., 2013).”
BackgroundOverview of Mechanisms Underlying Neuroimmune Diseases
Sonar, S. A., & Lal, G. (2024) · Springer eBooks · doi:10.1007/978-3-031-24297-7_1-1
Zhang, Y., Lei, L., Zou, Q., Li, Y., Liu, Y., Fang, Y., & Zhou, L. (2024) · Research Square · doi:10.21203/rs.3.rs-4813314/v1
Overview of Mechanisms Underlying Neuroimmune Diseases
Sonar, S. A., & Lal, G. (2024) · Springer eBooks · doi:10.1007/978-3-031-60006-7_1
Epigenetic effects of AtreMorine in Parkinson’s disease
Naidoo, V., Martínez-Iglesias, O. A., & Cacabelos, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18722-3.00009-8
Özata, G., Wise, R. M., Cardona‐Alberich, A., Mayeen, N. F., Müller, S. A., Lichtenthaler, S. F., Zecca, L., & Burbulla, L. F. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.04.668126
Cross-talk between genetic and environmental factors in Parkinson's disease
Fernagut, P., & Dehay, B. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-21992-4.00001-4
Hassouna, I. A., Hassanein, O., El-Elaimy, I. A., & Ibrahim, H. M. (2026) · Neurochemical Research · doi:10.1007/s11064-026-04715-9
“To confirm, TLR4 knockout lowered the number of activated microglial cells and protected against SNpc dopaminergic degeneration, demonstrating that TLR4 contributes to neuroinflamma - tion [63].”
TLR4-mediated neuroimmune signalling drives proprioceptive neuron degeneration in Friedreich ataxiaPreprint
Chellapandi, D. M., Antoine-Uhart, P., Pilotto, F., & Puccio, H. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.28.721289
Li, Y., Guo, L., Yu, X., & Peng, C. (2026) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2025.31 · Cited by 1
Sexually dimorphic roles of toll-like receptors in the central nervous system
Elkabes, S. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106830
Metadata
- Authors
- Noelker, C., Morel, L., Lescot, T., Osterloh, A., Alvarez-Fischer, D., Breloer, M., Henze, C., Depboylu, C., Skrzydelski, D., Michel, P. P., Dodel, R. C., Lu, L., Hirsch, E. C., Hunot, S., & Hartmann, A.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Bernhard Nocht Institute for Tropical Medicine (DE)
- Philipps University of Marburg (DE)
- Corresponding author
- Hunot, Stéphane
- Hartmann, Andreas
- ORCID
- Venue
- Scientific Reports
- Published
- 2013-03-06
- Volume
- 3
- Issue
- 1
- Pages
- 1393-1393
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC3589722
- OpenAlex
- W2093718309
- Cited by
- 164
- References
- 23
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 9 · 2023: 14 · 2022: 10 · 2021: 17 · 2020: 18 · 2019: 13 · 2018: 16 · 2017: 10 · 2016: 15 · 2015: 12 · 2014: 11 · 2013: 2
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Update notices
- correction (2023-01-16)
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/3.0/ (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nc-nd)
- Funders
- Michael J. Fox Foundation for Parkinson's Research
- Deutsche Forschungsgemeinschaft
- Institut National de la Santé et de la Recherche Médicale
- Centre National de la Recherche Scientifique
- Uniklinikum Giessen und Marburg
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- TLR4, Parkinson's disease, MPTP, dopaminergic neuron death, microglial activation, neuroinflammation, TLR4-deficient mice, substantia nigra, immune response
- MeSH terms
- Animals, Corpus Striatum, Dopamine, Homovanillic Acid, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Cell Death, Microglia, Mice, Knockout, Parkinsonian Disorders, Toll-Like Receptor 4, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.